Cobimetinib
- Generic Name
- Cobimetinib
- Brand Names
- Cotellic
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21F3IN3O2
- CAS Number
- 934660-93-2
- Unique Ingredient Identifier
- ER29L26N1X
- Background
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metasta...
- Indication
Cobimetinib is indicated in combination with vemurafenib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. As a single agent, cobimetinib is also indicated for the treatment of adult patients with histiocytic neoplasms.
- Associated Conditions
- Histiocytic Neoplasm, Metastatic Melanoma, Unresectable Melanoma
- Associated Therapies
- -
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Melissa Burgess, MD
- Target Recruit Count
- 5
- Registration Number
- NCT02230306
- Locations
- ๐บ๐ธ
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
๐บ๐ธMohammed Milhem, MD, Iowa City, Iowa, United States
๐บ๐ธAnna Pavlick, MD, New York, New York, United States
A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02136524
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 673
- Registration Number
- NCT02091141
- Locations
- ๐บ๐ธ
University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States
๐บ๐ธMD Anderson, Houston, Texas, United States
๐บ๐ธUniversity of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 385
- Registration Number
- NCT02060188
- Locations
- ๐บ๐ธ
Local Institution - 0028, Gilbert, Arizona, United States
๐บ๐ธLocal Institution - 0004, Los Angeles, California, United States
๐บ๐ธLocal Institution - 0036, Boston, Massachusetts, United States
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 24
- Registration Number
- NCT02036086
- Locations
- ๐จ๐ฆ
The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
๐จ๐ฆRoyal Victoria Hospital, Montreal, Quebec, Canada
๐จ๐ฆSunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 153
- Registration Number
- NCT01988896
- Locations
- ๐บ๐ธ
Massachusets General Hospital Clinical Trial Network and Institute, Boston, Massachusetts, United States
๐บ๐ธCompass Oncology, Portland, Oregon, United States
๐บ๐ธTexas Oncology, P.A., Arlington, Texas, United States
A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01986166
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01974258
Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation
- Conditions
- Interventions
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Fondazione Melanoma Onlus
- Target Recruit Count
- 11
- Registration Number
- NCT01959633
- Locations
- ๐ฎ๐น
Fondazione G.Pascale, Napoli, Italy
A Study to Evaluate Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Participants
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01929876
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.